Recent Research in Curing Duchenne Muscular Dystrophy

As the chairman and CEO of Integrated Oncology Network, LLC, Jeffrey Goffman continues more than two decades of service in the health care industry. Jeffrey Goffman maintains involvement in several charitable organizations, including serving as the chairman of the board of directors for CureDuchenne.

The leading organization for Duchenne research, CureDuchenne promotes the development of drugs to treat the disease and provides education and support to the families of patients with Duchenne. A type of muscular dystrophy (genetic disorders resulting in muscle weakness), Duchenne affects young males. Almost 15,000 boys throughout the United States and more than 300,000 across the globe deal with it.

CureDuchenne continues to seek a cure and to keep abreast of research in the field. Recently, the organization announced some success in that regard from studies conducted by Capricor Therapeutics, Inc. Capricor announced at the 22nd Annual International Congress of the World Muscle Society that testing of its product, CAP-1002, had shown significant improvement of upper limb and cardiac function among young men with advanced stages of Duchenne.